# US 2006/0154859 A1 · Leptin antagonists

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0154859 A1
- Document ID: US20060154859A1
- Status: Published application
- Kind: A1
- Application number: 10/996,607
- Filed: 2004-11-26
- Published: 2006-07-13
- Earliest claimed: 2004-11-26
- Assignees: Yissum Research Development Company of the Hebrew University of Jerusalem; Universites Paris 6 et Paris 7; Institut Nationale de la Recherche Agronomique (INRA)
- Inventors: Arieh Gertler; Isabelle Callebaut; Jean Djiane
- Web page: https://patentgrep.com/patent/US20060154859A1

## CPC

- C07K 14/5759: {Products of obesity genes, e.g. leptin, obese (OB), tub, fat}
- A61K 47/60: the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention relates to synthetic leptin antagonists in which at least two amino acid residues of the sequence LDFI/S of the hydrophobic binding site at positions 39-42 of a leptin polypeptide sequence are substituted with different amino acid residues such that the site becomes less hydrophobic, and fragments of said leptin antagonists.

## Claims

### Claim 1

A synthetic leptin antagonist in which at least two amino acid residues of the sequence LDFI/S of the hydrophobic binding site at positions 39-42 of a leptin polypeptide sequence are substituted with different amino acid residues such that the site becomes less hydrophobic, and fragments of said leptin antagonist.

### Claim 2 (depends on 1)

A leptin antagonist of claim 1, wherein at least two of the amino acid residues at positions 39-42 are substituted with one or more amino acid residues selected from the group consisting of alanine, arginine, aspartatic acid, glutamic acid, glycine, lysine and serine.

### Claim 3 (depends on 2)

A leptin antagonist of claim 2, wherein said amino acid residue is alanine.

### Claim 4 (depends on 1)

A leptin antagonist of claim 1, wherein two of the amino acid residues at any of the positions 39-42 of a mammal leptin polypeptide sequence are substituted with alanine.

### Claim 5 (depends on 4)

A leptin antagonist of claim 4, wherein said mammal leptin is human leptin.

### Claim 6 (depends on 5)

A leptin antagonist of claim 5, wherein said human leptin antagonist is of the SEQ ID NO: 1 or SEQ ID NO: 2.

### Claim 7 (depends on 4)

A leptin antagonist of claim 4, wherein said mammal leptin is ovine leptin.

### Claim 8 (depends on 7)

A leptin antagonist of claim 7, wherein said ovine leptin antagonist is of the SEQ ID NO: 3 or SEQ ID NO: 4.

### Claim 9 (depends on 1)

A leptin antagonist of claim 1, wherein three of the amino acid residues at any of the positions 39-42 of a mammal leptin polypeptide sequence are substituted with alanine.

### Claim 10 (depends on 9)

A leptin antagonist of claim 9, wherein said mammal leptin is human leptin.

### Claim 11 (depends on 10)

A leptin antagonist of claim 10, consisting of the polypeptide of SEQ ID NO: 5.

### Claim 12 (depends on 9)

A leptin antagonist of claim 9, wherein said mammal leptin is ovine leptin.

### Claim 13 (depends on 12)

A leptin antagonist of claim 12, consisting of the polypeptide of SEQ ID NO: 6.

### Claim 14 (depends on 1)

A leptin antagonist of claim 1, wherein the four amino acid residues at positions 39-42 of the human leptin polypeptide sequence are substituted with alanine, said leptin antagonist consisting of the polypeptide of SEQ ID NO: 7.

### Claim 15 (depends on 1)

The leptin antagonist of claim 1, wherein the four amino acid residues at positions 39-42 of the ovine leptin polypeptide sequence are substituted by alanine, said leptin antagonist consisting of the polypeptide of SEQ ID NO: 8.

### Claim 16 (depends on 1)

An isolated DNA molecule encoding a leptin antagonist of claim 1.

### Claim 17 (depends on 16)

A DNA molecule of claim 16 selected from the group consisting of the DNA sequences of SEQ ID NOs: 9, 10, 11, 12, 13, 14, 15 and 16.

### Claim 18 (depends on 1)

A synthetic leptin fragment of claim 1, in which at least two amino acid residues of the sequence LDFI/S of the hydrophobic binding site at positions 39-42 of a leptin polypeptide sequence are substituted with different amino acid residues such that the site becomes less hydrophobic, said fragment being a leptin antagonist.

### Claim 19 (depends on 1)

A synthetic leptin antagonist of claim 1 in pegylated form.

### Claim 20 (depends on 1)

A pharmaceutical composition comprising a synthetic leptin antagonist of claim 1, or a fragment thereof, and a pharmaceutically acceptable carrier.

### Claim 21 (depends on 20)

The pharmaceutical composition of claim 20 comprising the synthetic leptin antagonist in a pegylated form.

### Claim 22 (depends on 20)

The pharmaceutical composition of claim 20 for treatment of type II diabetes.
